Challenges for development of meningococcal vaccines in infants and children

References

• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med.129(6), 1327–1348 (1969).
   PubMed Web of Science ®Google Scholar
• Deasy A, Read RC. Genetic variation in pro-inflammatory cytokines and meningococcal sepsis. Curr. Opin. Infect. Dis.23(3), 255–258 (2010).
   PubMedGoogle Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N. Engl. J. Med.344(18), 1378–1388 (2001).
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine27, B51–B63 (2009).
   PubMed Web of Science ®Google Scholar
• Cartwright KA, Stuart JM, Jones DM, Noah ND. The stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol. Infect.99(3), 591–601 (1987).
   PubMed Web of Science ®Google Scholar
• Gold R, Goldschneider I, Lepow ML, Draper TF, Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J. Infect. Dis.137(2), 112–121 (1978).
   PubMed Web of Science ®Google Scholar
• Caugant DA, Høiby EA, Magnus P et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J. Clin. Microbiol.32(2), 323–330 (1994).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol. Infect.134(3), 556–566 (2006).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet Infect. Dis.7(12), 797–803 (2007).
   PubMed Web of Science ®Google Scholar
• Miller E. Immunological and safety aspects to consider for meningococcal conjugate vaccines. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Koumaré B, Ouedraogo-Traoré R, Sanou I, et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine25(Suppl. 1), A37–A41 (2002).
   Google Scholar
• Delrieu I. Emergence of Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso before introduction of a monovalent meningococcal conjugate vaccine against serogroup A. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Swartley JS, Marfin AA, Edupuganti S et al. Capsule switching of Neisseria meningitidis. Proc. Natl Acad. Sci. USA94(1), 271–276 (1997).
   PubMed Web of Science ®Google Scholar
• Schroeder HR Jr, Mortari F, Shiokawa S, Kirkham PM, Elgavish RA, Bertrand FE 3rd. Developmental regulation of the human antibody repertoire. Ann. NY Acad. Sci.764, 242–260 (1995).
   PubMed Web of Science ®Google Scholar
• Siegrist CA. Neonatal and early life vaccinology. Vaccine19(25–26), 3331–3346 (2001).
   PubMed Web of Science ®Google Scholar
• Adkins B. T-cell function in newborn mice and humans. Immunol. Today20(7), 330–335 (1999).
   PubMedGoogle Scholar
• Philbin VJ, Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr. Res.65(5 Pt 2), 98R–105R (2009).
   PubMed Web of Science ®Google Scholar
• Glezen WP. Effect of maternal antibodies on the infant immune response. Vaccine21(24), 3389–3392 (2003).
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N et al. Neisseria meningitidis group B correlates of protection and assay standardization – international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine24(24), 5093–5107 (2005).
   Google Scholar
• Janeway C, Travers P, Walport M, Shlomihik M. In: Immunobiology 1st Edition – the Humoral Immune Response. Garland Publishing, NY, USA (2001).
   Google Scholar
• De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA285(2), 177–181 (2001).
   PubMed Web of Science ®Google Scholar
• Lebel MH, Tapiero BF, Saintonge F. Immunogenicity of bivalent AC polysaccharide meningococcal vaccine in children aged 6 through 24 months. JAMA285(12), 1578–1579 (2001).
   PubMedGoogle Scholar
• Al-Mazrou Y, Khalil M, Borrow R et al. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect. Immun.73(5), 2932–2939 (2005).
   PubMed Web of Science ®Google Scholar
• Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J. Clin. Invest.56(6), 1536–1547 (1975).
   PubMed Web of Science ®Google Scholar
• Heath PT. Haemophilus influenzae type B conjugate vaccines: a review of efficacy data. Pediatr. Infect. Dis. J.17(9), S117–S122 (1998).
   PubMed Web of Science ®Google Scholar
• MacLennan JM, Shackley F, Heath PT et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA283(21), 2795–2801 (2000).
   PubMed Web of Science ®Google Scholar
• Auckland C, Gray S, Borrow R et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J. Infect. Dis.194, 1745–1752 (2006).
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis.197(5), 737–743 (2008).
   PubMed Web of Science ®Google Scholar
• Findlow J. The UK experience with meningococcal vaccines conjugated to different carrier proteins. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Rennels M, King J, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J.23(5), 429–435 (2004).
   PubMed Web of Science ®Google Scholar
• Snape MD, Perrett KP, Ford KJ et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA299(2), 173–184 (2008).
   PubMed Web of Science ®Google Scholar
• La Force FM. Introduction of a new group A meningococcal conjugate vaccine (MenAfriVac) in the African meningitis belt. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• LaForce FM, Konde K, Viviani S, Préziosi MP. The meningitis vaccine project. Vaccine25(Suppl. 1), A97–A100 (2007).
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet2(8346), 355–357 (1983).
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14(2), 195–207; discussion 208–210 (1991).
   PubMedGoogle Scholar
• Morley SL, Cole MJ, Ison CA et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr. Infect. Dis. J.20(11), 1054–1061 (2001).
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• O’Hallahan J, McNicholas A, Galloway Y, O’Leary E, Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. NZ Med. J.122(1291), 48–59 (2009).
   PubMedGoogle Scholar
• Thornton V, Lennon D, Rasanathan K et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine24(9), 1395–1400 (2006).
   PubMedGoogle Scholar
• Jackson C, Lennon DR, Sotutu VT et al. Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Arch. Dis. Child.94(10), 745–751 (2009).
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd B, Streefland M, van der Ley P et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine28(30), 4810–4816 (2010).
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Donets MA, Schmiel DH et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine28(31), 5057–5067 (2010).
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine19(17–19), 2688–2691 (2001).
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl Acad. Sci. USA107(45), 19490–19495 (2010).
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis.51(10), 1127–1137 (2010).
   PubMed Web of Science ®Google Scholar
• Vesikari T. Immunogenicity of an investigational multicomponent meningococcal serogroup B vaccine in healthy infants at 2, 4 and 6 months of age. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Dull P. Early clinical development of a novel multicomponent meningococcal serogroup B vaccine (4CMenB). Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Findlow J. Characterisation of fHbp, nhba, NadA, PorA and sequence type in meningococcal group B case isolates collected in England and Wales in the epidemiological year 2007/2008, and the potential coverage of an investigational group B vaccine. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010.
   Google Scholar
• Nissen M. A randomized, placebo-controlled, double-blind, Phase I trial of ascending doses of meningococcal group B rLP2086 vaccine. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases. Graz, Austria, 13–17 May 2008.
   Google Scholar
• Lan T, Kandimalla ER, Yu D et al. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc. Natl Acad. Sci. USA104(34), 13750–13755 (2007).
   PubMed Web of Science ®Google Scholar
• Metlay JP, Fishman NO, Joffe M, Edelstein PH. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine24(4), 468–475 (2006).
   PubMed Web of Science ®Google Scholar
• Maiden MCJ, Stuart JM. On behalf of the UK meningococcal carriage group. Carriage of serogroup C meningococci one year after meningococcal C conjugate polysaccharide vaccination. Lancet359, 1829–1830 (2002).
   PubMed Web of Science ®Google Scholar